TY - JOUR T1 -住院患者COVID-19康复血浆:非盲、随机临床试验JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01471 -2021欧元SP - 2101471 AU -关根身上,利奥盟——攻击,Beatriz AU - Fabro,米菲r . AU - Cipolatt Murillo m . AU -马查多,拉斐尔·r·g . AU - Durigon爱迪生l . AU - Parolo Edino AU -佩莱格里尼,何塞奥古斯托。s . AU - Viana滨诉AU -施瓦兹,帕特丽夏盟——葡京,蒂亚戈c . AU -多拉,何塞·米格尔·s . AU - Portich茱莉亚p . AU -巴斯,亚历山德拉a盟——新罗,露琪亚盟——Balsan Almeri m . AU - Schirmer费利佩·达席尔瓦AU -弗朗茨,朱莉安娜p . m . AU - da-Silveira曾m . AU - Breunig拉奎尔c . AU -彼得森Viviana AU - Sosnoski蒙娜丽莎盟——MesquitaNanci F. AU - Volpato, Fabiana Caroline Z. AU - Sganzerla, Daniel AU - Falavigna, Maicon AU - Rosa, Regis G. AU - Zavascki, Alexandre P. A2 -，2019冠状病毒病(COVID-19)住院患者恢复期血浆(CP)治疗的效果仍不确定。本研究探讨CP对这些患者临床改善的作用。方法:这是一项由研究者发起、随机、平行、开放标签、优势的临床试验。患者被随机(1:1)分配到两个输注CP加标准护理(SOC)或单独SOC。主要结果是入组后28天临床改善的患者比例。结果160例患者(每组80例)完成了试验，其中危重型占66.3%，重症占33.7%。 The median age was 60.5 years (interquartile range [IQR], 48–68), 58.1% were men and the median time from symptom onset to randomisation was 10 days (IQR, 8–12). Neutralising antibodies titres >1:80 were present in 133 (83.1%) patients at baseline. The proportion of patients with clinical improvement on day 28 was 61.3% in the CP+SOC and 65.0% in the SOC group (difference, −3.7%; 95% Confidence Interval [CI], −18.8%-11.3%). The results were similar in the subgroups of severe and critically ill. There was no significant difference between CP+SOC and SOC groups in prespecified secondary outcomes, including 28-day mortality, days alive and free of respiratory support and duration of invasive ventilatory support. Inflammatory and other laboratorial markers values on days 3, 7 and 14 were similar between groups.Conclusions CP+SOC did not result in a higher proportion of clinical improvement on at day 28 in hospitalised patients with COVID-19 compared to SOC alone.In this open-label, randomised clinical trial, two infusions of convalescent plasma therapy plus standard of care compared to standard of care did not result in a higher proportion of clinical improvement on day 28 in hospitalized patients with severe COVID-19. ER -